DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Tesevatinib
Tesevatinib
Deciphering Molecular Mechanisms and Prioritizing Therapeutic Targets in Cardio-Oncology
Therapeutic Inhibition of VEGF Signaling and Associated Nephrotoxicities
Leptomeningeal Metastases from Solid Tumors: Recent Advances in Diagnosis and Molecular Approaches
Cell-Cycle and DNA-Damage Response Pathway Is Involved In
Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
Kadmon Holdings, Inc. Annual Report 2018
Management of Her2+ Brain and Leptomeningeal Disease
Targeted Therapies for Brain Metastases from Breast Cancer
Supplementary Material For
Figure S1. Effect of 4NQO, A-1155463 Or Their Combination on General Transcription, Translation, and Specific Apoptotic Proteins
Receptor Tyrosine Kinase-Targeted Cancer Therapy
Dual Targeting of the Epidermal Growth Factor Receptor Using
Center for Neuro-Oncology Dana Farber/Brigham and Women’S Cancer Center
Stembook 2018.Pdf
Current Challenges and Opportunities in Treating Glioblastomas
Get Ready for the Future of Gene Variant Interpretation with Molecular Health Guide
2018 Medicines in Development for Cancer
Clinical Trial Announcement
Top View
Kadmon Holdings, Inc. (Exact Name of Registrant As Specified in Its Charter) ______
Epidermal Growth Factor Receptor; Erbb-1; HER1
Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer Funda Meric-Bernstam1,2,3, Amber M
Central Nervous System Failure in Korean Breast Cancer Patients with HER2-Enriched Subtype: Korean Radiation Oncology Group 16-15 Multicenter Retrospective Study
Design of a GAK/EGFR Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma
Therapeutic Inhibition of VEGF Signaling and Associated Nephrotoxicities
Analysis and Monitoring Ctcs and Ctdna in CSF Demonstrates Clinical Concordance in Tesevatinib Treated NSCLC Patients with LM
Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells
International Nonproprietary Names for Pharmaceutical Substances (INN)
Emerging Therapeutic Agents for Lung Cancer Bhagirathbhai Dholaria, William Hammond, Amanda Shreders and Yanyan Lou*
Product Data Sheet
Current Standards and New Treatment Insights in HER2-Driven Metastatic Breast Disease
Clinical Development of Targeted and Immune Based Anti-Cancer Therapies N
Kadmon Holdings, Inc. (Exact Name of Registrant As Specified in Its Charter)
Network Analytics for Drug Repurposing in COVID-19
Anti-Angiogenic Therapies in the Management of Glioblastoma
Catalytic Receptors
Emerging Uses of Biomarkers in Lung Cancer Management: Molecular Mechanisms of Resistance
3-Resistance-Mechanisms-To-Anti-Her2-Therapies.Pdf
Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond
2020 Medicines in Development for Children
Novel Treatments for Polycystic Kidney Disease
Targeted Lapatinib Anti-HER2/Erbb2 Therapy Resistance in Breast Cancer: Opportunities to Overcome a Difficult Problem
Protein Tyrosine Kinase/RTK
Delivery and Efficacy of Targeted Therapeutics and Imaging Agents For
UNITED STATES SECURITIES and EXCHANGE COMMISSION Washington, D.C
Clinical Trial Announcement
Glioblastoma: Pathogenesis and Current Status of Chemotherapy and Other Novel Treatments
Protein Tyrosine Kinase/RTK
Updated Insights on EGFR Signaling Pathways in Glioma
World Journal of Nephrology
Current Challenges and Opportunities in Treating Glioblastomas